Apogee Therapeutics, Inc.
APGE
$43.93
$2.074.95%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 6.75% | 20.66% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.85% | 29.30% | |||
| Operating Income | 16.85% | -29.30% | |||
| Income Before Tax | 17.77% | -37.09% | |||
| Income Tax Expenses | 361.11% | -- | |||
| Earnings from Continuing Operations | 17.67% | -37.13% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 17.67% | -37.13% | |||
| EBIT | 16.85% | -29.30% | |||
| EBITDA | 17.04% | -29.28% | |||
| EPS Basic | 19.01% | -36.03% | |||
| Normalized Basic EPS | 19.11% | -36.00% | |||
| EPS Diluted | 19.01% | -36.03% | |||
| Normalized Diluted EPS | 19.11% | -36.00% | |||
| Average Basic Shares Outstanding | 1.65% | 0.80% | |||
| Average Diluted Shares Outstanding | 1.65% | 0.80% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||